In Q1 2023, Avoro Capital Advisors held 32 positions worth $6.2B. They initiated 32 new positions. Their largest holding was HZNP ($764.0M).
Frequently asked questions
What stocks did Avoro Capital Advisors own in Q1 2023?
Avoro Capital Advisors held 32 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include HZNP, APLS, UTHR, SRPT, ARGX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Avoro Capital Advisors's portfolio worth in Q1 2023?
Avoro Capital Advisors's tracked biotech portfolio was worth $6.2B across 32 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Avoro Capital Advisors buy in Q1 2023?
Avoro Capital Advisors initiated 32 new positions in Q1 2023, including HZNP, APLS, UTHR, SRPT, ARGX and 27 more. They also increased 0 existing positions.
What did Avoro Capital Advisors sell in Q1 2023?
Avoro Capital Advisors did not fully exit any positions in Q1 2023.
Is Avoro Capital Advisors a biotech fund?
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Want AI analysis, insider signals, and catalyst overlays for Avoro Capital Advisors?
View latest Avoro Capital Advisors portfolio →